Schizophrenia Clinical Trials in Garden Grove, California

13 studies are recruiting for schizophrenia in Garden Grove, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

   The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Local Institution - 0037, Garden Grove, California

   Locations

   59 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT07686263 on ClinicalTrials.gov

2. A Study of Brenipatide in Adult Participants With Schizophrenia

   The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment pe…

   Stage

   Phase 2

   Ages

   18 to 55

   Site

   Collaborative Neuroscience Research, LLC, Garden Grove, California

   Locations

   103 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07410507 on ClinicalTrials.gov

3. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

   ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

   Stage

   Phase 2

   Ages

   18 to 65

   Site

   Clinical Site, Garden Grove, California

   Locations

   42 in total

   Run by

   MapLight Therapeutics

   See if you can join NCT07459647 on ClinicalTrials.gov

4. Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

   This is a multicenter, global, 26-week, open-label study to assess the safety and tolerability of lumateperone in pediatric patients with schizophrenia, bipolar disorder or autism spectrum disorder.

   Stage

   Phase 3

   Ages

   5 to 17

   Site

   National Institute Of Clinical Research, Garden Grove, California

   Locations

   64 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06229210 on ClinicalTrials.gov

5. A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

   The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   CNS Network, Garden Grove, California

   Locations

   8 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07615426 on ClinicalTrials.gov

6. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

   Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   CenExel CNS - Garden Grove (Collaborative Neuroscience Research) Site, Garden Grove, California

   Locations

   73 in total

   Run by

   Otsuka Pharmaceutical Development & Commercialization, Inc.

   See if you can join NCT06894212 on ClinicalTrials.gov

7. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

   This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   CenExel, Garden Grove, California

   Locations

   13 in total

   Run by

   LB Pharmaceuticals Inc.

   See if you can join NCT07363577 on ClinicalTrials.gov

8. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

   This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Garden Grove, California

   Locations

   57 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07114874 on ClinicalTrials.gov

9. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

   The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

   Stage

   Phase 3

   Ages

   18 to 65

   Site

   Neurocrine Clinical Site, Garden Grove, California

   Locations

   20 in total

   Run by

   Neurocrine Biosciences

   See if you can join NCT07227818 on ClinicalTrials.gov

10. A Study to Evaluate the Effect of KarXT on Urological Safety

    The purpose of this study is to characterize the effect of KarXT on voiding dynamics and urological safety in participants with DSM-5 schizophrenia.

    Stage

    Phase 4

    Ages

    18 to 65

    Site

    CenExel CNS - Garden Grove, Garden Grove, California

    Locations

    13 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07221877 on ClinicalTrials.gov

11. NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

    The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Neurocrine Clinical Site, Garden Grove, California

    Locations

    15 in total

    Run by

    Neurocrine Biosciences

    See if you can join NCT07105098 on ClinicalTrials.gov

12. Study of ALTO-101 in Patients With Schizophrenia

    This is a Phase 2, double-blind, placebo-controlled, two-way crossover study to compare the efficacy of ALTO-101T versus placebo in change in electroencephalogram (EEG) cognitive processing markers and measures of cognition. Additional goals are to assess pharmacokinetic (PK), safety, and tolerabil…

    Stage

    Phase 2

    Ages

    21 to 55

    Site

    Site 5038, Garden Grove, California

    Locations

    14 in total

    Run by

    Alto Neuroscience

    See if you can join NCT06502964 on ClinicalTrials.gov

13. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage

    Phase 3

    Ages

    18 to 65

    Site

    Reviva site, Garden Grove, California

    Locations

    18 in total

    Run by

    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov